Juvenile idiopathic arthritis – classification and methods of treatment
DOI:
https://doi.org/10.12775/JEHS.2023.18.01.009Keywords
Juvenile idiopathic arthritis, arthritis, pediatric, biological treatmentAbstract
Introduction Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease of unknown etiology that affect children. According to the definition of JIA, the disease begins before the age of 16 and lasts more than 6 weeks. The International League of Associations for Rheumatology (ILAR) has divided juvenile idiopathic arthritis into seven categories: systemic, oligoarticular, polyarticular RF (-), polyarticular RF (+), psoriatic, enthesitis-related and undifferentiated arthritis. Purpose The aim of this review is to present the classification, etiopathogenesis, diagnosis, treatment and complications of juvenile idiopathic arthritis. Methods Literature searches in PubMed, Google Scholarship, and open source books were used to gather information. Results Complex interactions between cells of the immune system are responsible for the pathophysiology of JIA and indicate the need to divide the disease into clinical subtypes, the heterogeneity of which requires different therapeutic actions. There are many groups of drugs with different mechanisms of action used in the treatment of JIA, including: T lymphocyte inhibitors, anti-TNFα, JAK inhibitors, IL-1 and IL-6 blockers. Despite the great progress and the commitment of scientists, there is still no treatment strategy to completely stop the development of the disease. Conclusions Scientific research conducted around the world has led to the recognition of numerous pathways leading to the formation of the inflammatory process and the symptoms of JIA. Knowledge of these mechanisms allows scientists to conduct research on further drugs, the aim of which is to find a treatment strategy that prevents permanent joint damage, improves treatment results, and enables sustainable remission. It is necessary to expand knowledge about the pathways responsible for the formation of the inflammatory process, the interruption of which would allow complete inhibition of the development of the disease.
References
Martini, A., Lovell, D.J., Albani, S. et al. Juvenile idiopathic arthritis. Nat Rev Dis Primers 8, 5 (2022). https://doi.org/10.1038/s41572-021-00332-8;
Zaripova LN, Midgley A, Christmas SE, Beresford MW, Baildam EM, Oldershaw RA. Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches. Pediatr Rheumatol Online J. 2021 Aug 23;19(1):135. doi: 10.1186/s12969-021-00629-8. PMID: 34425842; PMCID: PMC8383464;
McCurdy D, Parsa MF. Updates in Juvenile Idiopathic Arthritis. Adv Pediatr. 2021 Aug; 68:143-170. doi: 10.1016/j.yapd.2021.05.014. PMID: 34243850;
d'Angelo DM, Di Donato G, Breda L, Chiarelli F. Growth and puberty in children with juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2021 Mar 12;19(1):28. doi: 10.1186/s12969-021-00521-5. PMID: 33712046; PMCID: PMC7953722;
Żuber Z. Młodzieńcze idiopatyczne zapalenie stawów. Pediatr Dypl. 2012;16(2):23-32;
Thatayatikom A, Modica R, De Leucio A. Juvenile Idiopathic Arthritis. [Updated 2022 Jun 23]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554605;
https://www.mp.pl/podrecznik/pediatria/chapter/B42.87.4.1.2.1;
Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet. 2011 Jun 18;377(9783):2138-49. doi: 10.1016/S0140-6736(11)60244-4. PMID: 21684384;
Hou X, Qu H, Zhang S, Qi X, Hakonarson H, Xia Q, Li J. The Multi-Omics Architecture of Juvenile Idiopathic Arthritis. Cells. 2020 Oct 15;9(10):2301. doi: 10.3390/cells9102301. PMID: 33076506; PMCID: PMC7602566;
Crayne CB, Beukelman T. Juvenile Idiopathic Arthritis: Oligoarthritis and Polyarthritis. Pediatr Clin North Am. 2018 Aug;65(4):657-674. doi: 10.1016/j.pcl.2018.03.005. PMID: 30031492;
Lee JJY, Schneider R. Systemic Juvenile Idiopathic Arthritis. Pediatr Clin North Am. 2018 Aug;65(4):691-709. doi: 10.1016/j.pcl.2018.04.005. PMID: 30031494;
Gowdie PJ, Tse SM. Juvenile idiopathic arthritis. Pediatr Clin North Am. 2012 Apr;59(2):301-27. doi: 10.1016/j.pcl.2012.03.014. PMID: 22560572;
Espinosa M, Gottlieb BS. Juvenile idiopathic arthritis. Pediatr Rev. 2012 Jul;33(7):303-13. doi: 10.1542/pir.33-7-303. PMID: 22753788;
Clarke SL, Sen ES, Ramanan AV. Juvenile idiopathic arthritis-associated uveitis. Pediatr Rheumatol Online J. 2016 Apr 27;14(1):27. doi: 10.1186/s12969-016-0088-2. PMID: 27121190; PMCID: PMC4848803;
Rosenthal A, Janow G. Enthesitis-Related Juvenile Idiopathic Arthritis. Pediatr Rev. 2019 May;40(5):256-258. doi: 10.1542/pir.2017-0177. PMID: 31043447;
https://www.mp.pl/podrecznik/pediatria/chapter/B42.87.4.1.2.3;
Barut K, Adrovic A, Şahin S, Kasapçopur Ö. Juvenile Idiopathic Arthritis. Balkan Med J. 2017 Apr 5;34(2):90-101. doi: 10.4274/balkanmedj.2017.0111. PMID: 28418334; PMCID: PMC5394305;
https://www.mp.pl/podrecznik/pediatria/chapter/B42.87.4.1.2.3.2;
Ansell BM. Juvenile psoriatic arthritis. Baillieres Clin Rheumatol. 1994 May;8(2):317-32. doi: 10.1016/s0950-3579(94)80021-9. PMID: 8076390;
Giancane G, Alongi A, Ravelli A. Update on the pathogenesis and treatment of juvenile idiopathic arthritis. Curr Opin Rheumatol. 2017 Sep;29(5):523-529. doi: 10.1097/BOR.0000000000000417. PMID: 28538013;
Onel K, Rumsey DG, Shenoi S. Juvenile Idiopathic Arthritis Treatment Updates. Rheum Dis Clin North Am. 2021 Nov;47(4):545-563. doi: 10.1016/j.rdc.2021.07.009. Epub 2021 Sep 2. PMID: 34635291;
Dąbkowska K, Wojdas M, Winsz-Szczotka K. Juvenile idiopathic arthritis – diagnostic and therapeutic procedures. Farmacja Polska 2019. 75. 34-43. 10.32383/farmpol/116306;
Cimaz R, Maioli G, Calabrese G. Current and emerging biologics for the treatment of juvenile idiopathic arthritis. Expert Opin Biol Ther. 2020 Jul;20(7):725-740. doi: 10.1080/14712598.2020.1733524. Epub 2020 Mar 2. PMID: 32116038;
Bovid KM, Moore MD. Juvenile Idiopathic Arthritis for the Pediatric Orthopedic Surgeon. Orthop Clin North Am. 2019 Oct;50(4):471-488. doi: 10.1016/j.ocl.2019.06.003. Epub 2019 Aug 6. PMID: 31466663;
Garner AJ, Saatchi R, Ward O, Hawley DP. Juvenile Idiopathic Arthritis: A Review of Novel Diagnostic and Monitoring Technologies. Healthcare (Basel). 2021 Dec 4;9(12):1683. doi: 10.3390/healthcare9121683. PMID: 34946409; PMCID: PMC8700900;
Giancane G, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO). Treatment of juvenile idiopathic arthritis: what's new? Curr Opin Rheumatol. 2019 Sep;31(5):428-435. doi: 10.1097/BOR.0000000000000632. PMID: 31169547;
https://www.mp.pl/podrecznik/pediatria/chapter/B42.87.4.1.1.#127130;
Erkens R, Esteban Y, Towe C, Schulert G, Vastert S. Pathogenesis and Treatment of Refractory Disease Courses in Systemic Juvenile Idiopathic Arthritis: Refractory Arthritis, Recurrent Macrophage Activation Syndrome and Chronic Lung Disease. Rheum Dis Clin North Am. 2021 Nov;47(4):585-606. doi: 10.1016/j.rdc.2021.06.003. Epub 2021 Aug 21. PMID: 34635293;
Romicka AM, Ruperto N, Gutowska-Gregorczyk G. The Polish version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp. Rheumatol. 2001;19(4 Suppl 23):121-125;
Ravelli A, Minoia F, Davì S, Horne A, Bovis F, Pistorio A, Aricò M, Avcin T, Behrens EM, De Benedetti F, Filipovic L, Grom AA, Henter JI, Ilowite NT, Jordan MB, Khubchandani R, Kitoh T, Lehmberg K, Lovell DJ, Miettunen P, Nichols KE, Ozen S, Pachlopnik Schmid J, Ramanan AV, Russo R, Schneider R, Sterba G, Uziel Y, Wallace C, Wouters C, Wulffraat N, Demirkaya E, Brunner HI, Martini A, Ruperto N, Cron RQ; Paediatric Rheumatology International Trials Organisation; Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology Collaborative Study Group; Histiocyte Society. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol. 2016 Mar;68(3):566-76. doi: 10.1002/art.39332. Epub 2016 Feb 9. PMID: 26314788;
Grom AA, Mellins ED. Macrophage activation syndrome: advances towards understanding pathogenesis. Curr Opin Rheumatol 2010; 22: 561– 6;
Smolewska E., Żuber Z.: Aktualne cele, możliwości i perspektywy leczenia młodzieńczego idiopatycznego zapalenia stawów w Polsce i na świecie. Via Medica. 2016, 2(1): 14–20;
Rutkowska-Sak L., Wiland P.: Ocena aktywności przebiegu młodzieńczego idiopatycznego zapalenia stawów. Reumatologia News. 2016, 1: 193–202;
Woroń J, Wordliczek J, Dobrogowski J.: Porównanie niesteroidowych leków przeciwzapalnych (NLPZ). Medycyna po Dyplomie 2011, 6(183): 55–63;
Kaszuba A., Pastuszka M., Kaszuba A.: Miejscowe glikokortykosteroidy w leczeniu chorób skóry – zalecane standardy postępowania. Forum Medycyny Rodzinnej 2009, 3(5): 347–358;
Ringold S, Weiss PF, Beukelman T, Dewitt EM, Ilowite NT, Kimura Y, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children Zaripova et al. Pediatric Rheumatology (2021) 19:135 Page 13 of 14 receiving biologic medications. Arthritis care & research. 2013;65(10):1551– 63;
Adams A, Lehman TJ Update on the pathogenesis and treatment of systemic onset juvenile idiopathic arthritis. Curr Opin Rheumatol 2005; 7: 612-616;
Lien G., Ueland T., Godang K., Selvaag A.M., Førre Ø.T., Flatø B.: Serum levels of osteoprotegerin and receptor activator of nuclear factor -κB ligand in children with early juvenile idiopathic arthritis: a 2-year prospective controlled study. Pediatr Rheumatol Online J. 2010, 8: 30. doi: 10.1186/1546-0096-8-30;
Ho ACH, Wong SN, Leung LCK, Chan WKY, Chong PCY, Tse NKC, Yeung RHM, Kong SY, Lee KP. Biological disease-modifying antirheumatic drugs in juvenile idiopathic arthritis of polyarticular course, enthesitis-related arthritis, and psoriatic arthritis: a consensus statement. Hong Kong Med J. 2020 Feb;26(1):56-65. doi: 10.12809/hkmj198195. PMID: 32077861;
McInnse I, Schett G Cytokines in the pathogenesis of rheumatoid arthritis. Curr Opin Rheumatol 2005; 7: 612-616;
Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359:810–820;
Tappeiner C, Mesquida M, Adán A, et al. Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol. [Internet]. 2016 [cited 2019 Sep 22]; 43:2183–2188;
Maggi L, Cosmi L, Simonini G, et al. T cell subpopulations in juvenile idiopathic arthritis and their modifications after biotherapies. Autoimmun Rev. 2016;15:1141–1144. Elsevier B.V.;
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Weronika Pawłocik, Laura Wojtala, Weronika Pawlak, Julia Szymańska, Agnieszka Możdżyńska, Lena Musiał, Ewa Grabowska, Kamil Kapłon, Katarzyna Pacek, Izabela Kamińska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 729
Number of citations: 0